CM. Read why NTLA stock has potential with upcoming 2025 data and a growing $12B market for Transthyretin Amyloidosis.

CAMBRIDGE, Mass., March 26, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ...

Epicrispr has raised $68m in the initial close of its Series B financing round to commence the clinical trial of EPI-321 for ...

Epicrispr Biotechnologies has raised $68m in the initial close of its Series B financing round to commence the clinical trial of its disease-modifying therapy, EPI-321, for facioscapulohumeral ...

This story is republished from STAT, the health and medicine news site that’s a partner to the Globe. Sign up for STAT’s free Morning Rounds newsletter here. Beam Therapeutics said Monday that ...

For many years, orphan drugs for rare diseases have been a draw for pharma companies, offering high prices, swift regulatory reviews, and often extended marketing exclusivity – but there are ...

In October, CRISPR Therapeutics co-founder Emmanuelle Charpentier and Intellia co-founder Jennifer Doudna shared the 2020 Nobel Prize in Chemistry for their work on CRISP/Cas9.

With drugs on the horizon for treating and possibly preventing transthyretin amyloid cardiomyopathy, cardiologists are ...

The company specialises in gene-modulating therapies, focusing on treatments for neuromuscular diseases. Credit: metamorworks/Shutterstock. Epicrispr Biotechnologies ...